Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort study.
Kosuke EbinaToru HiranoYuichi MaedaWataru YamamotoMotomu HashimotoKoichi MurataAkira OnishiSadao JinnoRyota HaraYonsu SonHideki AmuroTohru TakeuchiAyaka YoshikawaMasaki KatayamaKeiichi YamamotoMakoto HiraoYasutaka OkitaAtsushi KumanogohKen NakataPublished in: Clinical rheumatology (2021)
After adjustment by potent confounders, SAR, BAR, and TOF showed similar discontinuation rates due to lack of effectiveness and toxic adverse events. Key Points • This is the first retrospective multicenter study that aimed to clarify the retention rates and reasons for discontinuation of SAR, BAR, and TOF in patients with RA.